| TRADING CENTER |
| Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxac... - Business Wire | |
| Aradigm Announces Third Quarter 2009 Financial Results - Business Wire |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| ACL | Alcon Inc | 160.64 | 2.92 / 1.85% | 24.49 |
| BAX | Baxter International Inc | 56.69 | 0.22 / 0.39% | 15.92 |
| BDX | Becton Dickinson & Co | 78.05 | 0.74 / 0.96% | 15.86 |
| 2008 Revenue: | $251,000.0 | Headquarters: Hayward, CA |
| Employees: | 38 | CEO: Dr. Igor Gonda, Ph.D. |
| Net Income: | $-22,608,000.0 | Industry: Medical Supplies |
| Market Cap: | $15.1 M | Website: www.aradigm.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| ARDM | 0.14 | -0.01 / -4.00% | 0.15 | 0.15 | 0.14 | Profile Chart News |